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Genotype-based personalised nutrition for  
obesity prevention and treatment: are we there yet?
Introduction
According to De Caterina,1 the interaction between diet and 
genotype is bidirectional. On the one hand, the environment 
(nutrients) can affect gene expression (nutrigenomics). On the other 
hand, genes can moderate the effect of environmental factors, such 
as dietary intake, on disease development (nutrigenetics). Recent 
research has also indicated that both under- and overnutrition can 
contribute to heritable changes in the genome, without changes in 
deoxyribonucleic acid (DNA) sequence (epigenetics). These changes 
are the result of molecular modifications of DNA through methylation, 
as well as histone (DNA packaging protein) modification.2,3 
Epigenetic effects are specifically prominent during pregnancy, 
including the periconceptional period, but also during neonatal 
development, puberty, and in the aged.3 Genes that may specifically 
hold epigenetic memories of early life experiences include 
those directly associated with energy intake, storage and use.3 
It is possible that epigenetics may influence obesity phenotype 
indicators. The findings by Lawlor et al,4 that maternal overnutrition 
may contribute to the transfer of obesity from one generation to the 
next via epigenetic effects, supports this possibility. 
To date, most research on nutrigenetics has focused on single-
nucleotide polymorphisms (SNPs).5 SNPs are point mutations in 
genes that account for most genetic variance involving differences 
in DNA sequence.6 Results emanating from this work support the 
notion that interactions between genes, diet, other lifestyle factors, 
disease, and time (life cycle span), contribute to the risk of most 
polygenic nutrition-related diseases.7-10
When considering the association between genotype and disease 
risk, it is important to bear in mind that individual susceptibility 
SNPs, involved in the development of polygenic diseases, typically 
make a relatively small contribution to the overall homeostasis, 
function and health of an individual.11 It follows that the presence of 
susceptibility SNPs does not necessarily result in the development 
of the disease in question. It must further be considered that a 
particular SNP could have both susceptibility and protective effects. A 
well-known example that illustrates this concept involves the C677T 
polymorphism in the methylenetetrahydrofolate reductase (MTHFR) 
gene. MTHFR plays a role in the remethylation of homocysteine to 
methionine.12 The TT variant has been shown to result in increased 
homocysteine levels, increasing the risk for neural tube defects and 
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cardiovascular disease.13 In contrast, Sharp and Little14 concluded 
in their review that individuals with the TT variant may have a lower 
risk of colon cancer. Evidence shows that this decreased risk may be 
attenuated by the use of multivitamin supplements.15 
The interpretation of nutritional genomics research and the 
application thereof in nutrition-related health care is clearly complex. 
To ensure evidence-based practice, the research design and 
methodology applied in the investigation of relevant associations, 
and confirmation of causality, should be appropriate and rigorous.10
Research design and methods for nutrigenetics 
research
The first line of evidence in nutrigenetics involves the establishment 
of associations between a particular genotype and one, or more, 
phenotype indicators of a particular disease (Table 1). In the case of 
obesity, phenotype indicators could include body mass index (BMI), 
waist circumference, percentage body fat, and related variables. For 
personalisation of nutrition interventions, the next step would be to 
establish the effect of the interaction between genotype and dietary 
indicators, e.g. total energy intake, on phenotype indicators. Once 
this association has been established, causality should be confirmed 
in an appropriately designed study (Table I). The outcome of causality 
testing can advise the formulation of genotype-based personalised 
dietary guidelines. Most publications on nutrigenetics report on 
associations between various genes and phenotype indicators. 
Publications on the effect of the interaction between genotypes 
and dietary indicators on phenotype indicators are less common, 
while appropriately designed interventions to confirm causality are 
extremely limited. 
Genotype-based personalised nutrition for improved 
health outcomes
Genotype-based personalised nutrition typically involves genotyping 
for a number of susceptibility SNPs, associated with the prevention, 
or management, of a particular disease. Dietary advice is then 
Table I: Summary of pertinent points for research design and methods in nutrigenetics research
Research steps Criteria for robust research Challenges/limitations
Step 1
Establish associations for 
hypotheses formulation:
Genotype X phenotype 
indicator
Effect of genotype X lifestyle 
(diet) indicator on phenotype 
indicator
Study design: prospective observation of cohorts (vs. cross-sectional 
observational designs) to determine associations.
Appropriate sample size to ensure representativeness.





Almost total lack of assessment of lifestyle (diet) 
indicators. 
Step 2
Confirmation of causality 
or hypothesis testing 
(interventions)
Prospective interventions to confirm causality.
Appropriate sample size for sufficient statistical power.
Use of appropriate genetic markers, robust (valid) lifestyle (diet) and phenotype 
indicators or outcomes.
Prospective sampling of genotype groups.
Equal number of subjects in the variant and wild type homozygote and 
heterozygote groups.
Rotation of interventions across all genotype groups, and across race groups as 
relevant, which requires consecutive weigh loss periods and return to baseline 
weight, to “test” each “type of diet” in each of the three genotypes
Confirmation of compliance. 
Poor study design.
Small samples
Sampling bias, retrospective genotyping.
Almost total lack of assessment and control for 
lifestyle (diet) indicators, as well as compliance 
thereto. 
Short duration of weight loss interventions (< 6 
months). 
Lack of rotation across genotype groups, as it is 
extremely challenging, if not impossible.
Steps 1 and 2 Use of appropriate statistical analyses or tests or modelling.
Validation of statistical models.
Consideration of multiple-test burden that may result in false positives.
Control for confounders or interactions, including gene-gene interactions, age, 
gender, race, disease, medication use, and geographical variation.
Consolidation of outcomes in meta-analytic approaches.
Consideration of systems genetics for integrative studies of gene-gene lifestyle 
(diet)-disease-time interactions. 
Lack of control of confounders and validation of 
statistical modelling.
Lack of meta-analyses on effect of genotype X 
lifestyle (diet) indicator on phenotype indicator, as 
well as confirmation of causality.
Journal bias favours publication of positive results.
Compiled from Joost et al,8 Kalupahana and Moustaid-Moussa,9 Hall, Morley, and Lucke, 11 Wittwer et al,12 Vimaleswaren and Loos,16 Caulfield,17 Ioannidis et al,18 Rimbach and Minihane,19 and Bouchard and Agurs-Collins20 
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personalised to the individual’s genotype to ensure optimal 
prevention or treatment outcomes. With this in mind, the clinical 
application of such screening tests needs to be considered. Should 
screening only apply to individuals with a family history of a particular 
disease, or those with diagnosed risk indicators, or who present with 
the disease? Should healthy individuals with no diagnosable risks 
of a disease, or family history thereof, be screened? The latter may 
result in intervention in asymptomatic individuals, for a disease that 
may never develop,7,21 as the predictive value of susceptibility SNPs 
is low.8
For application in evidence-based practice, susceptibility testing 
should meet the following criteria: 
•	 The clinical validity of the test must have been clearly 
established,22 following the steps outlined in Table I. 
•	 Evidence-based, acceptable and accessible interventions 
must be available to those who test positive for a particular 
susceptibility genotype.21 
•	 Health professionals, including dietitians, who are competent 
in interpreting the outcomes of such tests, and in counselling 
clients accordingly, must be in place.11,22
Whether or not these criteria are met by commercialised susceptibility 
gene screening, has been questioned in different forums.
Evans et al24 contend that available interventions are often untested. 
They also mention that recommendations are very likely to be based 
on presumed benefit, rather than on outcomes of well-designed 
interventions. When considering genotype-based nutrition (lifestyle) 
counselling for obesity treatment, the counselling would most likely 
involve behaviour strategies aimed at changing dietary intake 
(decreased energy intake), and physical activity (increased energy 
expenditure), to a greater or lesser extent. These recommendations 
are in line with current non-genotype-based recommendations for 
the prevention and management of obesity. Whether or not gene 
screening would result in the fine tuning of such recommendations to 
measurably improve prevention or treatment outcomes significantly, 
is still ambiguous. 
Genotype-based personalised nutrition for the 
prevention and treatment of obesity
Obesity develops when energy intake exceeds energy expenditure. 
According to Stipanuk,23 the interaction between genotype and 
environmental factors possibly explains the majority of variance in 
body weight: “Obesity is most likely to occur when a genetically 
susceptible individual encounters an environment that is conducive 
to obesity”.
Identification of susceptibility genes for obesity initially followed 
the candidate gene approach (Table II). The latest (2005) and last 
update of the obesity gene map, reported 127 genes associated with 
obesity phenotype indicators.24 In 2010, Vimaleswaran and Loos16 
reported that findings for only 12 of these genes were replicated 
in 10, or more, studies. When considering these results, it must 
be borne in mind that many other studies report no, or opposite, 
associations for these 12 genes. The conclusions regarding true 
associations thus remain contradictory. In recent years, a number 
of larger-scale studies and meta-analyses have shown robust 
associations between four of these genes and obesity indicators. 
These four genes include melanocortin 4 receptor gene (MC4R; 
involved in the regulation of food intake and energy homeostasis), 
adrenergic B3 receptor (ADRB3; involved in regulation of lipolysis 
and thermogenesis), prohormone convertase 1/3 gene(PCSK1; 
involved in activating prohormones to hormones involved in energy 
metabolism regulation), and brain-derived neurotropic factor 
gene (BDNF; involved in eating behaviour, body weight regulation 
and hyperactivity) (as summarised by Vimaleswaran and Loos).16 
Research on the effect of the interaction between genotype for these 
genes and diet (and other lifestyle) indicators on obesity indicators is 
scarce, while well-designed interventions to confirm causality could 
not be traced. 
Table II: Identification of susceptibility genes for obesity: candidate gene 
and genome-wide association approaches
Candidate gene approach
First edition of the obesity gene map, based on the candidate gene 
approach. Published in 1996. 
Yearly updates, with the last edition published in 2005.
Hypothesis-driven identification of candidate genes, based on current 
understanding of biology and pathophysiology.
Genes selected based on functional role in relevant metabolic pathways, 
evidence from animal studies, monogenic forms of obesity, and 
association studies. 
SNPs within, or near, candidate genes, for a condition or disease of 
interest, e.g. obesity, are considered.
Limited success, mainly due to small, inadequate samples.
Large samples or meta-analyses are needed to detect small effects  
(odds ratios 1.2-1.3).
Genome-wide association approach
Initiated in 2005. 
Investigates entire genome, with no prior assumptions regarding potential 
associations and functionality.
Aims to identify previously unsuspected loci associated with a condition  
or disease, e.g. obesity, in large samples.
Genome-wide association typically comprises two or more stages:
Stage 1: Discovery phase
Genotyping for > 100 000 gene variants across the genome. 
Testing for associations with disease or disease indicators with 
significance threshold: p-value < 5.0 x 10-8. 
This may result in false positive outcomes.
Stage 2: Replication phase
Significant associations identified in the discovery phase are taken 
forward for replication (validation). 
Only replicated findings are deemed to be “true hits”.
The next stages would involve fine mapping of relevant genetic regions 
(loci) to identify the functional single nucleotide polymorphisms, and 
subsequent identification of biological pathways that explain associations. 
Adapted from Vimaleswaren and Loos 16
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The complexity of translation of nutrigenetics-related information 
into evidence-based dietary guidelines can be illustrated using 
the ADRB3 Trp64Arg polymorphism that has been included in 
some commercial gene screens for personalisation of weight-loss 
recommendations, as an example. Meta-analysis of association 
studies has shown that Arg64-allele carriers have a 0.24 kg/m2 
higher BMI, compared to the Trp64Trp homozygotes in Asians.25 This 
association was not found in Caucasians.25,26 One of the very few 
studies on the effect of the interaction between the presence of the 
ADRB3 Trp64Arg polymorphism, and diet indicators on BMI (obesity 
phenotype indicator), was conducted by Miyaki et al27 in Japanese 
subjects. These researchers concluded that only Arg 64 allele carriers 
with the highest energy intakes exhibited an increased obesity risk. 
A number of researchers have also investigated the effect of the 
ADRB3 Trp64Arg polymorphism on the response to a standard 
conservative diet (thus not personalised according to genotype, 
and is not a confirmation of causality) in Caucasians (sample sizes 
25-85)27-30 and Asians (sample sizes 24-88).29-31 Asian, but not 
Caucasian, Arg64 allele carriers, were found to lose less weight and 
fat, especially visceral fat, when exposed to a conservative weight 
loss programme. Translation of these findings into genotype-based 
personalised weight-loss guidelines could involve recommendations 
for very low energy intakes and high levels of physical activity for 
Asian Arg64 allele carriers. Whether such genotype-based guidelines 
are truly effective should be tested in well-designed intervention 
studies, once causality has been established. No such research 
could be traced for the ADRB3 Trp64Arg polymorphism, indicating 
that screening for this SNP for personalisation of weight-loss diets 
would be premature at this point in time. 
According to Vimaleswaran and Loos,21 genome-wide association 
(GWA) scans are rapidly contributing to more insight in the field of 
obesity genetics. Through GWA scans, the FTO gene (fat-mass and 
obesity-associated gene) has been confirmed as the first gene that is 
unquestionably associated with common obesity. Ongoing research 
to identify the functional role of the FTO gene in relevant metabolic 
pathways, indicates that it is most probably implicated in controlling 
energy homeostasis and eating behaviour.34-39 Certain SNPs in this 
gene have also been associated with increases in BMI, as well 
as decreased lipolytic activity, independent of BMI.35,40 However, 
investigation of the effect of the interaction between FTO genotypes 
and diet indicators on obesity indicators, as well as confirmation of 
causality, is only beginning to emerge. 
The process of identifying further loci (specific locations of genes on 
chromosomes) associated with obesity is ongoing. Speliotes et al41 
reported 18 new loci that are associated with BMI at genome-wide 
significance level (p-value < 5.0 x 10-8), bringing the total number of 
such loci to 32. These findings were based on a GWA meta-analysis, 
including approximately 249 796 individuals of European ancestry. 
Speliotes et al41 predict that 284 further common loci with effects 
on BMI, similar to the confirmed loci, may be identified in future. It 
is important to note that the combined effect of the SNPs at the 32 
confirmed loci on the variance in BMI is a modest 1.45%, bearing 
in mind that the estimated heritability of obesity is estimated to be 
40-70%.40 Furthermore, resequencing and fine mapping of most 
of the identified loci still need to be carried out to identify causal 
SNPs. Clear connections to the biology of weight regulation are 
also not known for most of the loci. Speliotes et al41 emphasise that 
Table III: Ethics-related points for consideration in the implementation of genotype-based personalised nutrition
Key aspect Points to consider
Robust causality and intervention 
effectiveness (utility) evidence
Limited availability of robust evidence, both for causality and effectiveness of genotype-based nutrition. This may result in non-
evidence-based recommendations and practice.
Analytical validity of genotyping Occurrence of laboratory errors in gene analyses. This may be especially true for uncontrolled online and home test kits. 
Informed consent Informed consent should cover the small risk contribution of single-nucleotide polymorphisms to polygenic diseases, available 
interventions, deoxyribonucleic acid banking or storage, and disclosure of information (intended and unintended) to relatives.
The testing of children for adult onset polygenic diseases (with parents’ consent) is a concern.
Test recommendation, interpretation 
and subsequent counselling
The availability of health professionals, including dieticians, who are competent in recommending, interpreting the outcomes of 
evidence-based tests for susceptibility single nucleotide polymorphisms, and appropriate counselling of clients. 
Privacy of information and 
discrimination 
Protection of privacy rights, i.e. right not to disclose test results to employers, medical and other insurance providers.
This is complicated by a lack of understanding of the nature of polygenic conditions, as well as the associated low-risk contribution of 
single-nucleotide polymorphisms by employers, insurance companies and society, which may result in various forms of discrimination. 
Advertising and media coverage of 
tests and public expectation
Advertisements and media coverage of commercial tests contribute to popular understanding of genotype-based personalised 
nutrition. They may not necessarily reflect evidence-based information, and may result in consumers being misled or even harmed. 
Public expectation is not necessarily motivated by the discovery of hidden abnormalities, but rather by the need for reassurance 
(that members of the public have no unusual problems).
Psychological impact A positive test may result in anxiety about increased disease risk, while the risk for development of the disease may be low. This 
might result in a fatalistic approach to personal health management, and might divert attention away from modifiable lifestyle risks.
A negative test may cause relief, resulting in a perception of “no genetic risk”, and a maverick approach (“No need to heed the 
guidelines for a healthy lifestyle”) .
Equity Availability to all sectors of the population.
Compiled from Bergman et al,8 Hall et al11 Levesque et al,42 Caulfield,17 DeBusk et al44 Harvey-Berino et al,45 Austin,46 McGovern et al,47 Kotze and Badenhorst,48Juth,49Huijgen et al.50
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genomic and experimental studies should be designed to elucidate 
functionality of the identified SNPs to provide much-needed insight 
into the biology of obesity.
Ethical issues related to genotype-based personalised 
nutrition
The increasing application of nutrigenetics research outcomes in 
genotype-based personalised nutrition has resulted in a discourse 
on potential ethical issues (Table III) on various platforms. According 
to Levesque et al,42 ethical developments in this field have been 
outpaced by nutrigenetics bioscience. Marketing of genotype-based 
personalised nutrition, especially online, and often without the input 
of appropriately qualified health professionals, now seems to be 
common practice. The potential nonadherence to relevant ethical 
principles, as mentioned in Table III, and lack of regulation in this 
regard, are serious concerns. It may be argued, as Ioannidis17 points 
out in an editorial on “personalised genetic prediction”, that “we 
adopted nearly all pregenomic-era tests without waiting for large, 
well designed, pragmatic randomised trials”. However, Ioannidis 
goes on to say that “we should not use past mistakes as an excuse 
for present inaction”. This view supports that of Caulfield,43 who, 
after their investigation of marketing dilemmas associated with 
current nutrigenetic services, concluded that it is important for more 
research to focus on the ethical, legal, and social aspects of such 
services, to ensure evidence-based, cost-effective practice in the 
prevention, or treatment of, common nutrition-related diseases. 
Conclusion
The escalation of identification of new loci associated with obesity 
indicators seems daunting. It is clear that translation of these 
insights into evidence-based guidelines for the prevention and 
treatment of obesity depends on the identification of causal SNPs 
in loci associated with BMI, establishment of the functional roles of 
identified SNPs in obesity-related metabolic pathways, investigation 
of the effect of the interaction between genotypes for specific SNPs 
and lifestyle (dietary intake and physical activity) indicators on 
obesity indicators, and confirmation of causality. All these outcomes 
should be integrated, using, for example, systems genetics to 
account for interactions between genes, diet, other lifestyle factors, 
disease, and time (life cycle span).
Conclusions formulated by various researchers on the translation of 
nutrigenetics research into personalised nutrition, including obesity 
prevention and management, indicate that generally, scientists hold 
the opinion that more research is necessary before evidence-based 
practice in this area can be guaranteed (Table IV). 
Ultimately, when behaviour change for the improvement of health 
outcomes is considered, whether genotype-based or not, some 
practice-related issues will remain. The most pertinent of these are 
that people will continue to develop diseases, while non-compliance 
to prevention or disease management guidelines, disparities in 
access to health services, and the potential for unproven and 
fraudulent medical practices and malpractice, will remain as 
challenges.2 In an editorial in Nature outlook, Grayson51 summarises 
the situation as follows: “Some people predict an age of diets 
customised to individual energy needs and disease susceptibility. 
But no matter how good the science is, or how well we are able to 
exploit food as an agent of healthfulness, we will still be eating for 
pleasure for some time yet”.
Meanwhile, while evidence seems to be accumulating for possible 
personalisation of nutrition based on genotype, Simopoulos52 
recommends the dissemination of dietary guidelines that are in line 
with the South African food based dietary guidelines at population 
level, to prevent disease and improve nutrition-related health 
outcomes in general. 
Table IV: Selected conclusions on the status of genotype-based personalised nutrition in peer-reviewed publications, 2007-2010
Author Quote
Joost et al8 “Current attempts to derive dietary recommendations, based on a few single SNPs presently known to be associated with particular complex 
diseases, appear largely experimental.”
Bergman et al7 “At present, the evidence base for genotype-specific dietary advice is limited. This may change, but it seems too early to estimate how autonomy and 
benefits should be balanced against each other in such a possible future.”
Rimbach and 
Minihane19 
“Although the evidence base in nutrigenetics is growing, with sufficient data to provide a ‘proof of principle’ of its potential utility in public health, this 
area currently suffers from a lack of consistent findings.”
Bouchard and 
Agurs-Collins20
“Finally, a major challenge will remain as to how to translate advances in our understanding of gene-behaviour interaction effects for public health 
consumption, when promoting weight gain prevention, and for clinical practice, in the context of treatment of obesity, and its associated morbidities.”
Kussmann et al3 “Genome-wide associations have identified a number of (candidate) risk loci for the development or (early) onset of certain diseases, including 
common and complex ones. However, the power of these risk loci to predict health trajectories, has, so far, been small, even if several loci have 
meanwhile been replicated, and taken together in a combined score.”
De Caterina1 “The background science is there, but how close are we to the goal of implementing personalised nutrition based on genetic knowledge? We are not 
there yet.”
Authors are presented in ascending order, based on publication date.
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